Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
243 participants
INTERVENTIONAL
2024-03-25
2028-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study consists of the following 3 parts, which are described in further detail below:
* Part 1 (Monotherapy Dose Escalation)
* Part 2 (Dose Optimization)
* Part 3 (Simon 2-Stage Evaluation)
Part 1 will enroll participants with a confirmed, relapsed/refractory malignancy with documented diagnosis of HER2 alterations including participants with brain metastases. Once a provisional maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) has been determined, Part 2 will enroll additional cohorts to optimize dose selection and to further evaluate the safety and preliminary efficacy of IAM1363. Following completion of Dose Optimization, Part 3 will be opened to enroll tumor-specific cohorts utilizing a Simon 2-Stage Minimax Design to evaluate IAM1363 at the selected dose(s).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IAM1363 Monotherapy
Treatment with IAM1363 capsules, dosed orally either once or twice daily in 21-day cycles.
IAM1363
Oral, immediate release capsules of IAM1363
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IAM1363
Oral, immediate release capsules of IAM1363
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have relapsed/refractory HER2-altered malignancy
* Have progression of disease after the last systemic therapy, or be intolerant of last systemic therapy
* Have radiographically measurable disease by RECIST v1.1 and/or RANO-BM
* Eastern Cooperative Oncology Group (ECOG) performance score 0-1
* Have adequate baseline hematologic, liver and renal function
* Have left ventricular ejection fraction (LVEF) ≥ 50%
Exclusion Criteria
* Infection with human immunodeficiency virus (HIV)-1 or HIV-2. Exception: Patients with well-controlled HIV (e.g., CD4 \>350/mm3 and undetectable viral load) are eligible
* Current active liver disease including hepatitis A, hepatitis B , or hepatitis C
* Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant small bowel resection that would preclude adequate absorption
* Uncontrolled diabetes
* History of solid organ transplantation
* History of Grade ≥2 CNS hemorrhage, or any CNS hemorrhage within 28 days before C1D1
* Patients requiring immediate local therapy for brain metastases
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Iambic Therapeutics, Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Iambic Therapeutics, Inc., Senior Medical Director
Role: STUDY_DIRECTOR
Iambic Therapeutics, Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCSD Moores Cancer Center
La Jolla, California, United States
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
University of Colorado Cancer Center
Aurora, Colorado, United States
University of Miami
Miami, Florida, United States
Comprehensive Hematology Oncology
St. Petersburg, Florida, United States
University of Chicago
Chicago, Illinois, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Henry Ford Cancer Institute
Detroit, Michigan, United States
START - Midwest Cancer Research Center
Grand Rapids, Michigan, United States
Saint Luke's Cancer Institute
Kansas City, Missouri, United States
Washington University School of Medicine
St Louis, Missouri, United States
RUTGERS Cancer Institute
New Brunswick, New Jersey, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Duke Cancer Institute
Durham, North Carolina, United States
University Hospital Cleveland Medical Center
Cleveland, Ohio, United States
Cleveland Clinic
Cleveland, Ohio, United States
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
Providence Cancer Institute
Portland, Oregon, United States
SCRI Oncology Partners
Nashville, Tennessee, United States
Vanderbilt Ingram Cancer Center
Nashville, Tennessee, United States
NEXT Oncology - Austin
Austin, Texas, United States
NEXT Oncology - Dallas
Dallas, Texas, United States
Mary Crowley Cancer Research
Dallas, Texas, United States
MD Anderson Cancer Center - University of Texas
Houston, Texas, United States
START Mountain Region
West Valley City, Utah, United States
NEXT Oncology - Virginia Cancer Specialists
Fairfax, Virginia, United States
Fred Hutchinson Cancer Center
Seattle, Washington, United States
Centre Georges François Leclerc
Dijon, , France
Institut Universitaire du Cancer de Toulouse (IUCT) Oncopole Institut Claudius Regaud "
Toulouse, , France
The START center Dublin
Dublin, Dublin, Ireland
Cork University Hospital, Wilton
Cork, , Ireland
Netherlands Cancer Institute-Antoni van Leeuwenhoek
Amsterdam, , Netherlands
Asan Medical Center
Seoul, , South Korea
Hospital Universitario Vall dHebron
Barcelona, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
START Madrid CIOCC, Hospital Universitario HM Sanchinarro
Madrid, , Spain
Hospital Universitario Virgen del Rocio
Seville, , Spain
Hospital Clinico Universitario de Valencia (INCLIVA)
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Iambic Therapeutics, Inc., Senior Medical Director
Role: CONTACT
Phone: 619-330-5499
Email: [email protected]
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IAM1363-01
Identifier Type: -
Identifier Source: org_study_id